LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS

被引：0
|
作者：
Magarotto, V. [1 ]
Bringhen, S. [1 ]
Hajek, R. [2 ,3 ]
Musto, P.
Goldaniga, M. C.
Ledda, A.
De Rosa, L.
Patriarca, F.
Morabito, F.
Troia, R. [1 ]
Genuardi, M. [1 ]
Berno, T.
Gambella, M. [1 ]
Pescosta, N.
Maisnar, V. [4 ,5 ]
Galli, M.
Falcone, A. P.
Rossi, D.
Offidani, M.
Boccadoro, M. [1 ]
Palumbo, A. [1 ]
机构：
[1] Univ Turin, Div Hematol, Myeloma Unit, Turin, Italy
[2] Univ Hosp Brno, Ostrava, Czech Republic
[3] Fac Med OU, Ostrava, Czech Republic
[4] Charles Univ Hradec Kralove, Fac Hosp, Dept Med 4, Hradec Kralove, Czech Republic
[5] Charles Univ Hradec Kralove, Fac Med, Hradec Kralove, Czech Republic
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P349
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [31] LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE (RD) VS. MELPHALAN-PREDNISONE-THALIDOMIDE (MPT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS): THE FIRST TRIAL
    Facon, T.
    Dimopoulos, M. A.
    Dispenzieri, A.
    Catalano, J. V.
    Belch, A.
    Hulin, C.
    Cavo, M.
    Pinto, A.
    Weisel, K. C.
    Ludwig, H.
    Bahlis, N.
    Banos, A.
    Tiab, M.
    Delforge, M.
    Cavenagh, J.
    Geraldes, C.
    Lee, J. J.
    Chen, C.
    Oriol, A.
    De La Rubia, J.
    Qiu, L.
    White, D.
    Binder, D.
    Anderson, K. C.
    Moreau, P.
    Attal, M.
    Knight, R.
    Chen, G.
    Van Oostendorp, J.
    Jacques, C. J.
    Ervin-Haynes, A.
    Benboubker, L.
    HAEMATOLOGICA, 2014, 99 : 220 - 221
  • [32] Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years
    Dimopoulos, Meletios Athanasios
    Palumbo, Antonio
    Hajek, Roman
    Kropff, Martin
    Petrucci, Maria Teresa
    Lewis, Philip
    Millar, Stefanie
    Zhang, Jingshan
    Mei, Jay
    Delforge, Michel
    BLOOD, 2011, 118 (21) : 1706 - 1707
  • [33] Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
    Gentile, Massimo
    Magarotto, Valeria
    Offidani, Massimo
    Musto, Pellegrino
    Bringhen, Sara
    Petrucci, Maria Teresa
    Gay, Francesca
    Larocca, Alessandra
    Uccello, Giuseppina
    Petrungaro, Annamaria
    Vigna, Ernesto
    Greco, Rosa
    Recchia, Anna Grazia
    Tripepi, Giovanni
    Ria, Roberto
    Di Raimondo, Francesco
    Palumbo, Antonio
    Morabito, Fortunato
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (03) : 244 - 250
  • [34] Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Hernandez, Miguel T.
    Martinez, Rafael
    Rosinol, Laura
    Ocio, Enrique M.
    Echeveste, Maria Asuncion
    de Oteyza, Jaime Perez
    Oriol, Albert
    Joan, Bargay
    Mercedes, Gironella
    Martin, Jesus
    Cabrera, Carmen
    Gutierrez, Norma
    Luisa, Martin Maria
    de la Rubia, Javier
    Blade, Joan
    Lahuerta, Juan Jose
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
  • [35] Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
    Usmani, S. Z.
    Cavenagh, J. D.
    Belch, A. R.
    Hulin, C.
    Basu, S.
    White, D.
    Nooka, A.
    Ervin-Haynes, A.
    Yiu, W.
    Nagarwala, Y.
    Berger, A.
    Pelligra, C. G.
    Guo, S.
    Binder, G.
    Gibson, C. J.
    Facon, T.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 243 - 258
  • [36] Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results.
    Palumbo, Antonio
    Falco, Patrizia
    Gay, Francesca
    Corradini, Paolo
    Crippa, Claudia
    Di Raimondo, Francesco
    Falcone, Antonietta
    Giuliani, Nicola
    Musto, Pellegrino
    Morabito, Fortunato
    Canepa, Letizia
    Gozzetti, Alessandro
    Caltagirone, Simona
    Zeldis, Jerome B.
    Knight, Robert D.
    Boccadoro, Mario
    Petrucci, Maria Teresa
    BLOOD, 2008, 112 (11) : 955 - 955
  • [37] A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m2) and autologous transplantation (MEL200) in newly diagnosed myeloma patients
    Palumbo, A. P.
    Cavallo, F.
    Di Raimondo, F.
    Ben Yehuda, D.
    Omade, P.
    Montefusco, V.
    Rossini, F.
    Harden, I.
    Caravita, T.
    Boccadoro, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] MELPHALAN, PREDNISONE, LENALIDOMIDE (MPR) VERSUS MELPHALAN(200 MG/M2) AND AUTOLOGOUS TRANSPLANTATION (MEL200) IN NEWLY DIAGNOSED MYELOMA PATIENTS: A PHASE III TRIAL
    Palumbo, A.
    Cavallo, F.
    Hardan, I.
    Redoglia, V.
    Petrucci, M. T.
    Scollo, C.
    Corradini, P.
    Siniscalchi, A.
    Di Raimondo, F.
    Boccadoro, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 351 - 351
  • [39] Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Hernandez, Miguel-T
    Martinez, Rafael
    Rosinol, Laura
    Ocio, Enrique M.
    Asuncion Echeveste, Maria
    Perez de Oteyza, Jaime
    Oriol, Albert
    Bargay, Joan
    Gironella, Mercedes
    Martin, Jesus
    Cabrera, Carmen
    De La Rubia, Javier
    Gutierrez, Norma C.
    Martin, Maria-Luisa
    Paiva, Bruno
    Angeles Montalban, Maria
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, Jesus F.
    BLOOD, 2014, 124 (21)
  • [40] UPDATED OVERALL SURVIVAL ANALYSIS OF THE FIRST STUDY: CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE VS MELPHALAN, PREDNISONE, AND THALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Facon, T.
    Dimopoulos, M. A.
    Hulin, C.
    Benboubker, L.
    Belch, A.
    Ludwig, H.
    Pinto, A.
    Attal, M.
    Cavo, M.
    Moreau, P.
    Schots, R.
    Meuleman, N.
    Weisel, K.
    Tiab, M.
    Lee, J. J.
    Butler, A.
    Marek, J.
    Chen, G.
    Ervin-Haynes, A.
    Fermand, J. P.
    HAEMATOLOGICA, 2015, 100 : 3 - 3
12345